Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) EBITDA (2024 - 2025)

Carlsmed's EBITDA history spans 2 years, with the latest figure at -$8.6 million for Q4 2025.

  • For Q4 2025, EBITDA fell 82.48% year-over-year to -$8.6 million; the TTM value through Dec 2025 reached -$28.6 million, changed N/A, while the annual FY2025 figure was -$29.6 million, 22.17% down from the prior year.
  • EBITDA reached -$8.6 million in Q4 2025 per CARL's latest filing, down from -$8.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.7 million in Q4 2024 to a low of -$8.6 million in Q4 2025.